Cargando…
Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance
Radiotherapy plays a central role in the treatment of cancer patients. Over the past decades, remarkable technological progress has been made in the field of conventional radiotherapy. In addition, the use of charged particles (e.g., protons and carbon ions) makes it possible to further improve dose...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033551/ https://www.ncbi.nlm.nih.gov/pubmed/32117774 http://dx.doi.org/10.3389/fonc.2020.00128 |
_version_ | 1783499694093107200 |
---|---|
author | Konings, Katrien Vandevoorde, Charlot Baselet, Bjorn Baatout, Sarah Moreels, Marjan |
author_facet | Konings, Katrien Vandevoorde, Charlot Baselet, Bjorn Baatout, Sarah Moreels, Marjan |
author_sort | Konings, Katrien |
collection | PubMed |
description | Radiotherapy plays a central role in the treatment of cancer patients. Over the past decades, remarkable technological progress has been made in the field of conventional radiotherapy. In addition, the use of charged particles (e.g., protons and carbon ions) makes it possible to further improve dose deposition to the tumor, while sparing the surrounding healthy tissues. Despite these improvements, radioresistance and tumor recurrence are still observed. Although the mechanisms underlying resistance to conventional radiotherapy are well-studied, scientific evidence on the impact of charged particle therapy on cancer cell radioresistance is restricted. The purpose of this review is to discuss the potential role that charged particles could play to overcome radioresistance. This review will focus on hypoxia, cancer stem cells, and specific signaling pathways of EGFR, NFκB, and Hedgehog as well as DNA damage signaling involving PARP, as mechanisms of radioresistance for which pharmacological targets have been identified. Finally, new lines of future research will be proposed, with a focus on novel molecular inhibitors that could be used in combination with charged particle therapy as a novel treatment option for radioresistant tumors. |
format | Online Article Text |
id | pubmed-7033551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70335512020-02-28 Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance Konings, Katrien Vandevoorde, Charlot Baselet, Bjorn Baatout, Sarah Moreels, Marjan Front Oncol Oncology Radiotherapy plays a central role in the treatment of cancer patients. Over the past decades, remarkable technological progress has been made in the field of conventional radiotherapy. In addition, the use of charged particles (e.g., protons and carbon ions) makes it possible to further improve dose deposition to the tumor, while sparing the surrounding healthy tissues. Despite these improvements, radioresistance and tumor recurrence are still observed. Although the mechanisms underlying resistance to conventional radiotherapy are well-studied, scientific evidence on the impact of charged particle therapy on cancer cell radioresistance is restricted. The purpose of this review is to discuss the potential role that charged particles could play to overcome radioresistance. This review will focus on hypoxia, cancer stem cells, and specific signaling pathways of EGFR, NFκB, and Hedgehog as well as DNA damage signaling involving PARP, as mechanisms of radioresistance for which pharmacological targets have been identified. Finally, new lines of future research will be proposed, with a focus on novel molecular inhibitors that could be used in combination with charged particle therapy as a novel treatment option for radioresistant tumors. Frontiers Media S.A. 2020-02-14 /pmc/articles/PMC7033551/ /pubmed/32117774 http://dx.doi.org/10.3389/fonc.2020.00128 Text en Copyright © 2020 Konings, Vandevoorde, Baselet, Baatout and Moreels. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Konings, Katrien Vandevoorde, Charlot Baselet, Bjorn Baatout, Sarah Moreels, Marjan Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance |
title | Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance |
title_full | Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance |
title_fullStr | Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance |
title_full_unstemmed | Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance |
title_short | Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance |
title_sort | combination therapy with charged particles and molecular targeting: a promising avenue to overcome radioresistance |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033551/ https://www.ncbi.nlm.nih.gov/pubmed/32117774 http://dx.doi.org/10.3389/fonc.2020.00128 |
work_keys_str_mv | AT koningskatrien combinationtherapywithchargedparticlesandmoleculartargetingapromisingavenuetoovercomeradioresistance AT vandevoordecharlot combinationtherapywithchargedparticlesandmoleculartargetingapromisingavenuetoovercomeradioresistance AT baseletbjorn combinationtherapywithchargedparticlesandmoleculartargetingapromisingavenuetoovercomeradioresistance AT baatoutsarah combinationtherapywithchargedparticlesandmoleculartargetingapromisingavenuetoovercomeradioresistance AT moreelsmarjan combinationtherapywithchargedparticlesandmoleculartargetingapromisingavenuetoovercomeradioresistance |